Physician profile
Terry Anthony Becker
NPI 1447334214
$3,341.34
in general payments reported to CMS, 2019-2025
30 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,129 · 2020: $463 · 2021: $663 · 2022: $369 · 2023: $342 · 2024: $186 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $717.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $726.72 | 2020-2025 | Vraylar, Qulipta, Viberzi |
| Amgen INC. | $359.85 | 2019-2024 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $345.24 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $253.19 | 2019-2022 | |
| Glaxosmithkline, LLC. | $247.25 | 2019-2023 | Shingrix, Arexvy |
| Novo Nordisk INC | $242.68 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $205.55 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $159.53 | 2019-2021 | |
| Allergan, INC. | $116.32 | 2019 | |
| Astellas Pharma US INC | $103.51 | 2022-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $98.35 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.57 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $68.09 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $41.66 | 2022 | |
| Avanir Pharmaceuticals, INC. | $37.16 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $34.29 | 2023-2024 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $27.67 | 2024 | Inspire |
| Ultragenyx Pharmaceutical INC. | $25.80 | 2020-2022 | |
| Genentech USA, INC. | $23.67 | 2020-2021 | |
| Organon LLC | $16.77 | 2022 | |
| Axsome Therapeutics, INC. | $14.52 | 2022 | |
| Lundbeck LLC | $14.43 | 2025 | Rexulti |
| Ironwood Pharmaceuticals, INC | $14.36 | 2019 | |
| Eisai INC. | $14.08 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.70 | 2022 | |
| Biogen, INC. | $12.63 | 2021 | |
| Sanofi Pasteur INC. | $12.45 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.04 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.